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Capsule: Our review of 15 studies suggests an association between diminished ovarian reserve 25 
and recurrent pregnancy loss. There is a need to evaluate the best prognostic tools for diminished 26 




Abstract (250) 28 
Objective: To evaluate the association between Diminished Ovarian Reserve (DOR) in women 29 
at risk of Recurrent Pregnancy Loss (RPL) using Ovarian Reserve Tests (ORTs) 30 
Design: Systematic review and meta-analysis 31 
Setting: N/A 32 
Patient(s): Women with history of RPL 33 
Intervention(s): We systematically reviewed major electronic databases (MEDLINE, EMBASE, 34 
Web of Science and Scopus) until May 2019 for studies that evaluated the incidence of DOR in 35 
women with RPL. We assessed study quality using the Newcastle-Ottawa Scale and meta-36 
analyzed data using a random-effect model.  37 
Main Outcome Measure(s): Association between RPL and DOR 38 
Results: We included fifteen studies (n=3082women) reporting on six ORTs (AMH, AFC, FSH, 39 
LH, Estradiol, FSH:LH ratio). More women with RPL seemed to have DOR compared to those 40 
with non-RPL as measured by low AMH levels (OR 2.77, 95%CI 1.41-5.46, p=0.03, I2=0%) and 41 
AFC (OR 2.45 95%CI 1.16-5.19, p=0.02, I2=59%). Women with unexplained RPL also seemed 42 
to have a higher association with DOR compared to those with RPL of known aetiology, 43 
measured by low AMH levels (OR 3.23 95%CI 1.81-5.76, p<0.0001, I2=0%). No statistically 44 
significant differences were found in the levels of any of the remaining ORTs between those 45 
groups of women.  46 
Conclusions: There is an apparent association between diminished ovarian reserve and recurrent 47 
pregnancy loss. Low AMH and AFC levels could predict higher odds for pregnancy loss but 48 
more studies are needed to evaluate their prognostic value in the management of women with 49 





Systematic review registration: Prospero CRD42018114673 52 





Recurrent Pregnancy Loss (RPL) affects 1-2% of women of reproductive age (1) and contributes 55 
to long-term adverse pregnancy outcomes in affected couples.(2) A clear aetiology cannot be 56 
determined in up to 50% of cases.(3,4) The advent of microarray analysis of miscarried tissue 57 
can help to determine between normal and abnormal pregnancies with up to 95% of couples 58 
being given a cause for their pregnancy losses.(5) Abnormal pregnancies conceived with an 59 
abnormal or low-quality oocytes, which is more common with advancing maternal age, could be 60 
a potential contributing factor to RPL in this group of women.(6) Evaluating ovarian reserve 61 
directly could, therefore, help to predict the reproductive potential and optimize the care 62 
provision for women at high risk of RPL.(7) 63 
 64 
Various biochemical and sonographic tests have been developed to quantitatively assess the 65 
ovarian reserve, predominantly for women undergoing assisted conception, including Anti-66 
Müllerian Hormone (AMH), basal Follicle Stimulating Hormone (FSH), basal Luteinising 67 
Hormone (LH), FSH:LH ratio, basal Estradiol (E2) and Antral Follicle Count (AFC).(8) 68 
However, there is uncertainty on the ability of these tests to evaluate the quality of remaining 69 
oocytes in addition to their quantity. Their predictive value for reproductive outcomes of women 70 
with diminished ovarian reserve (DOR) also remains imprecise.(1)  71 
 72 
We conducted a systematic review of the literature to evaluate the evidence on the association 73 
between RPL and DOR and evaluate the use of ORTs in this context.  74 
 75 




We conducted this systematic review using a prospectively registered protocol (PROSPERO 77 
CRD42018114673) and reported in line with the PRISMA statement.  78 
 79 
Search Strategy 80 
We searched major electronic databases (MEDLINE, EMBASE, Web of Science and Scopus) 81 
from inception until May 2019 for all primary studies evaluating the association between DOR 82 
and RPL in women who underwent static ovarian reserve testing using any identified marker.  83 
We used Medical Subject Headings (MeSH) terms for ‘recurrent pregnancy loss’ and ‘ovarian 84 
reserve tests’ and combined them with AND or OR Boolean operators. We did not apply any 85 
search filters or limitations. We conducted forward and backward citation tracking of included 86 
articles to identify any articles not captured in our electronic search. Non-English language 87 
publications were translated if deemed relevant. Our exclusion criteria were: studies including 88 
women with a medical condition or treatment known to be associated with RPL or ORTs; oocyte 89 
donation recipients; interventional studies; animal studies; case reports; commentaries; review 90 
articles and editorials.  91 
  92 
Study Selection and Inclusion Process 93 
We performed a two-stage screening and inclusion process. Firstly, two independent reviewers 94 
(EH and SB) screened the titles and abstracts of potentially relevant citations to assess eligibility. 95 
In the second stage, we obtained full articles of selected citation and evaluated them against our 96 
inclusion criteria. Any disagreement was resolved by discussion with a third reviewer (BHA).   97 
  98 




We extracted data in duplicate onto an electronic database piloted among co-authors. We 100 
collected data on the following: name of authors, year of publication, country of publication, 101 
study population characteristics, cut-off values for diminished ovarian reserve, ovarian reserve 102 
test values in each group.  103 
We used the Newcastle-Ottawa Scale (NOS)(9) to assess the quality of the included studies in 104 
duplicate by two reviewers (EH and SB). Studies were awarded a maximum of four stars for 105 
selection, two for comparability and three for assessment of outcomes. Studies that scored four 106 
stars for selection, two stars of comparability and three stars for assessment of outcomes were 107 
considered to be of high quality. Scores of one star or less for selection, comparability or 108 
outcome assessment were considered to be of low quality. Any other score combinations were 109 
considered of medium quality. We did not perform a funnel plot analysis due to the small 110 
number of studies included. 111 
 112 
Statistical analysis 113 
We reported on dichotomous outcomes using Odd Ratio (OR) where possible. Studies reporting 114 
on differences in mean values were included in the systematic review but not in the quantitative 115 
meta-analysis. We performed a direct comparison meta-analysis using a random effect model 116 
and reported using OR and 95% Confidence Intervals (CI). We evaluated the heterogeneity in 117 
included studies using I2 statistics categorized as per the Cochrane Handbook thresholds to 118 
‘moderate’, ‘substantial’ or ‘considerable’. Sensitivity analysis was not conducted due to the 119 
small number of included studies for each ovarian reserve test. All statistical analyses were 120 
conducted in Microsoft Excel (Microsoft Excel v.2016, Microsoft Redmond, Washington) and 121 
RevMan (Review Manager (RevMan). V5.3. Copenhagen: The Nordic Cochrane Centre, The 122 






Characteristics of included studies 126 
Our search identified 2518 potentially relevant citations following deduplication. We assessed 127 
148 full articles against our eligibility criteria and included 15 observational studies reporting on 128 
3082 women and 6 ovarian reserve tests (AMH, FSH, Estradiol, LH, AFC and FSH:LH ratio). 129 
(Table 1). 130 
The majority of studies were case-control in design (12/15, 80.0%) and three studies were cohort 131 
(20.0%). Nearly one-third of included studies were published in Europe (5/15, 33.3%) and a 132 
quarter were published in North America (4/15, 26.7%). The majority were published in 133 
specialist journals (12/15, 80.0%). 134 
 135 
The definition of RPL in the inclusion criteria varied among included studies with the majority 136 
defining RPL as three or more miscarriages (11/15, 73.3%) whilst 4 of the 15 studies (26.7%) 137 
included women with two or more miscarriages. Seven studies included women specifically with 138 
consecutive miscarriages (7/15, 46.7%). Ten studies specifically stated their participants had first 139 
trimester (2/15, 13.3%) or <20-week gestation (8/15, 53.3%) pregnancy losses (Table 1). Ten 140 
studies compared women with RPL to women without a history of RPL (non-RPL) (10/15, 141 
63.3%) and five compared women with unexplained RPL (URPL) to those with explained RPL 142 
(ERPL) (5/15, 33.3%). The average age of participants was 32.0 years in the RPL group, 32.4 143 
years in the non-RPL group, 35.5 years in the URPL group and 34.3 years in the ERPL group. 144 
The control group for non-RPL consisted of women who were in-clinic seeking contraception, 145 




infertility with no history of miscarriage or history of RPL. One study described ‘no history of 147 
RPL’ as women who had two or fewer previous miscarriages.(10) 148 
 149 
The direct causes for ERPL in the included studies were: presence of thyroid peroxidase 150 
antibodies (TPOab), uterine abnormalities, thrombophilic defects, antiphospholipid syndrome 151 
(APLS), parental chromosomal abnormalities, thyroid abnormalities, diabetes mellitus (DM) and 152 
‘hormonal conditions’. Only six studies (6/15, 40.0%) reported a cut-off for defining DOR in 153 
their cohort thus allowing quantitative meta-analyses of data (Figure 1). 154 
 155 
Quality of included studies 156 
The overall quality of the included studies was medium with the majority of studies showing 157 
good quality for both population selection (12/15, 80.0%), and outcome assessment (13/15, 158 
86.7%). There was poor quality in selecting appropriate comparison groups in over half of the 159 
included studies (8/15, 53.3%), and only 4 studies showed good quality for their comparison 160 
methods (26.7%). (Supplemental figure 1) 161 
 162 
AMH 163 
Women with RPL had lower levels of AMH suggesting an association with DOR in three studies 164 
(7,10,11), however, this was not the case in two of the included studies with no significant 165 
difference in AMH levels between RPL and non-RPL groups.(12,13) One study by Pils et al(14)  166 
suggested lower AMH levels in women with URPL compared to ERPL (1.2 ng/mL [1.1; 2.7] vs. 167 
2.0 ng/mL [1.1; 2.7], p=0.037), however such association was not confirmed in the study by 168 




We pooled data from two studies reporting on DOR with AMH ≤1ng/mL (n=313 women).(7,11) 170 
Overall there was higher OR of 2.77 for DOR in the RPL group (95%CI 1.41-5.46, p=0.03, 171 
I2=0%) (Figure 2a). Similarly, a meta-analysis showed higher odds for DOR in women with 172 
URPL compared to ERPL (OR 3.23, 95%CI 1.81-5.76, p<0.0001, I2=0%) (n=772 women) 173 
(Figure 2b).(15–17)  174 
 175 
AFC 176 
Two studies reported on the association between DOR defined by an AFC ≤7 in RPL and non 177 
RPL women.(7,11) Pooled data of 313 women showed significantly higher odds for DOR in 178 
women with RPL compared to non-RPL (OR 2.45, 95%CI 1.16, 5.19, p=0.02, I2=59%) (Figure 179 
3).  180 
 181 
FSH 182 
Overall there was no clear difference in the levels of FSH between women with RPL and non-183 
RPL in three of the included studies,(11,18,19) one study suggested higher levels (7) and one 184 
suggested lower levels in the RPL group.(13) We pooled the data from two studies (n=313 185 
women) (7,11) reporting on DOR with an FSH ≥11U/L in RPL versus non-RPL women and 186 
found higher OR of 2.05 (95%CI 0.36-11.55, p=0.42) but there was high heterogeneity among 187 
included studies (I2=73%). (Supplemental figure 2a) Data from three studies (15–17) revealed no 188 
significant association with DOR reported by high FSH in women with URPL compared to 189 
ERPL (OR=1.85, 95%CI 0.72, 4.74, p=0.20, I2=39%) (n=359 women) (Supplemental figure 2b). 190 
The FSH:LH ratio evaluated by two studies (7,11) was not statistically different between RPL 191 






Overall there was no strong evidence of higher LH values associated with RPL with only one 195 
(18) of three studies (7,19) included suggesting a higher average compared to women with non-196 
RPL (4.5 ± 0.2 vs. 3.0 ± 1.4 IU/ml, p<0.001). Regan et al (20) used a threshold of LH ≥10IU/L 197 
to define DOR and suggested a higher association with RPL (9/30, 30.0%) compared to non-RPL 198 
women (1/17, 5.9%) (p<0.05). Only one study (14) evaluated LH levels between women with 199 
URPL and ERPL suggesting no significant differences.  200 
 201 
Estradiol 202 
There were no significant differences in levels of Estradiol between women with RPL and non-203 
RPL in six of the included studies.(7,11,18,19,21,22) Using a cut-off of ≥60nmol/L, those 204 
findings were supported by our meta-analysis using data from two studies (n=313 women) (7,11) 205 
with an OR of 1.94 (95%CI 0.16- 3.48, p=0.60, I2=94%) (Supplemental figure 3). Similarly, no 206 




Summary of findings 211 
In this systematic review, we highlight a potential association between diminished ovarian 212 
reserve and higher odds for RPL, especially in women with URPL. We aimed to evaluate the 213 
best ORT to screen for such association but due to the lack of standardized reporting thresholds, 214 
we are unable to make firm conclusions. However, the use of AMH and AFC seems to offer the 215 
best prognostic value which is consistent with their established convenience and reliability in 216 





Strengths and Limitations 219 
We conducted our review using a prospectively registered protocol and employing a 220 
comprehensive search strategy. We included all relevant study designs and evaluated the risk of 221 
bias in included studies in duplicate. We reported on all included studies and used a random 222 
effect model to pool data where possible.  223 
 224 
Our findings are not without limitations; although we identified a relatively large number of 225 
studies reporting on the association between ovarian reserve and RPL, there were considerable 226 
variations in population characteristics, test thresholds and reported outcomes which limited our 227 
ability to synthesis data meaningfully. Women with RPL represent a heterogeneous group; 228 
without a unanimous definition for RPL cases or the non-RPL comparator groups used across the 229 
studies included in this review, the possibility of contamination between groups must be 230 
considered.(25) Our meta-analyses consisted primarily of data from a small number of studies 231 
which limits the value of pooling data, thus, the findings should be interpreted with caution. We 232 
were unable to adjust for certain important effect modifiers such as age, ethnicity and the 233 
biochemical assays used to measure ORTs which could affect our findings. These are especially 234 
relevant to the prognostic value of AMH and AFC as they tend to decrease with advancing 235 
maternal age. Due to the small number of studies and limited information reported, a meta-236 
regression was not possible.  237 
 238 
Wider implications and future research 239 
Care for women with RPL remains a clinical challenge due to the limited range of available 240 




women limits the accuracy of prognostic screening to plan future treatment options. The advent 242 
of available array techniques for analysing miscarried tissue means an increasing awareness of 243 
the contribution of abnormal pregnancies to RPL so that specific investigations can be offered to 244 
those with higher risk of conceiving an abnormal pregnancy. The association between advancing 245 
maternal age, decreasing oocyte numbers, and the risk for aneuploidy RPL is well 246 
established.(27,28) Still, the efficacy of available treatment options such as assisted reproduction 247 
technologies (ARTs) including, preimplantation genetic testing for aneuploidy (PGT-A) and 248 
oocyte donation, in the management of RPL remains unclear.(29) Evaluating DOR and the 249 
associated risk of RPL could help this group of high-risk women and their caring health 250 
professionals to weigh in the available treatment options and to optimize their care.  251 
 252 
To date, there is still no universally accepted definition of DOR, which significantly hinders the 253 
potential to synthesise evidence and improve the care of women with RPL.(30) In this review, 254 
we also highlight the high variation in outcomes reporting which also reduced our ability to 255 
synthesise meaningful conclusions. Developing a core set of outcomes for RPL research and 256 
standardizing their definitions would help to resolve this issue.(31)  257 
 258 
Both AMH and AFC have been used to predict various reproductive outcomes in couples 259 
seeking fertility treatments such as predicting IVF success (32), live birth (33), and response to 260 
ovulation stimulation.(34) Our findings supporting their potential value to advice on the 261 
treatment options for women at risk of RPL fit with the overall prognostic value of these tests. 262 
Still, our estimates are imprecise due to several limitations such as the variations in available 263 
diagnostic essays (35), sonographic limitations (36), and the natural decline of these markers 264 




captured evidence on the use of static ORTs. Several other static tests are used in practice such as 266 
Inhibin B, ovarian volume and ovarian vascularity but we could not identify any relevant studies 267 
to evaluate their use in the context of RPL. Dynamic ORTs, such as Clomiphene Citrate 268 
Challenge Test (CCCT) and Gonadotrophin-releasing hormone Agonist Stimulation Test 269 
(GAST), which assess ovarian responses to exogenous stimulation, could be helpful to screen for 270 
DOR in women at risk of RPL, but future studies are needed to evaluate their prognostic value. 271 
Future large prospective cohort studies are also needed to evaluate the role of ORT screening for 272 
subfertility in clinical practice and to identify the test with the best cost-effective qualities.  273 
 274 
Conclusion 275 
There is an apparent association between diminished ovarian reserve and recurrent pregnancy 276 
loss. Low AMH and AFC levels could predict higher odds for pregnancy loss but more studies 277 
are needed to evaluate their prognostic value in the management of women with recurrent 278 
pregnancy loss.   279 
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Figure legends: 398 
Figure 1: The selection and inclusion process for studies evaluating the association between 399 
diminished ovarian reserve and recurrent pregnancy loss# 400 
Figure 2: Meta-analysis evaluating the association between diminished ovarian reserve (DOR) 401 
and recurrent pregnancy loss (RPL) using Anti-Mullerian Hormone levels (AMH)   402 
Figure 3: Meta-analysis evaluating the association between diminished ovarian reserve (DOR) 403 
defined using Antral Follicle Count (AFC) ≤7 in women with recurrent pregnancy loss (RPL) 404 
compared to non-RPL.  405 
Supplemental figure 1: The quality of included studies evaluating the association between 406 
dimineshed ovarian reserve and recurrent pregancny loss assessed using the Newcastle-Ottawa 407 
Scale. 408 
Supplemental figure 2: Meta-analysis evaluating the association between diminished ovarian 409 
reserve (DOR) and recurrent pregnancy loss (RPL) using Follicle stimulating hormone (FSH) 410 
Supplemental figure 3: Meta-analysis evaluating the association between diminished ovarian 411 
reserve (DOR) defined using Estradiol ≥60nmol/L in women with recurrent pregnancy loss 412 
(RPL) compared to non-RPL.  413 
